hCAP-D3: A Potential Drug Target and Biomarker (G23310)

Target Name: NCAPD3

NCBI ID: G23310

NCAPD3

hCAP-D3: A Potential Drug Target and Biomarker

Introduction

Natural products derived from plants have long been recognized as a rich source of bioactive molecules with diverse chemical profiles and potential therapeutic activities. One such natural product is hCAP-D3, a bioactive compound found in the essential oil of black pepper (Lippia oblonga), which has been shown to have anti-inflammatory and analgesic properties.

Recent studies have suggested that hCAP-D3 may have additional functions as a drug target and biomarker. In this article, we will explore the potential mechanisms by which hCAP-D3 may interact with the human body and the potential implications of these interactions.

Mechanisms of hCAP-D3 as a Drug Target

hCAP-D3 has been shown to interact with various cellular components and signaling pathways, including nuclear factor-kappa-B (NF-kappa-B), pain signaling pathways, and the blood-brain barrier. These interactions suggest that hCAP-D3 may have potential as a drug target for various diseases.

One of the key mechanisms by which hCAP-D3 may interact with the human body is through its effects on pain signaling pathways. Chronic pain is a significant public health issue, with estimates suggesting that the global burden of chronic pain is close to 100 million individuals . hCAP-D3 has been shown to inhibit pain signaling pathways, including the production of pro-inflammatory cytokines such as TNF-伪 and IL-1尾.

In addition to its potential anti-inflammatory effects, hCAP-D3 may also interact with pain signaling pathways to enhance the pain sensation. hCAP-D3 has been shown to increase the production of the neurotransmitter glutamate on sensory nerve endings, thereby enhancing pain perception.

Mechanisms of hCAP-D3 as a Biomarker

hCAP-D3 has also been shown to serve as a potential biomarker for various diseases. As a natural product derived from a plant, hCAP-D3 has been shown to have a low toxicity and low potential for adverse effects. This makes it a potential biomarker for various diseases, including pain, inflammation, and neurological disorders.

One of the key potential applications of hCAP-D3 as a biomarker is its potential to detect early stages of disease. hCAP-D3 has been shown to have potential as a diagnostic agent for various diseases, including neuroinflammatory disorders and pain conditions.

In addition to its potential as a diagnostic agent, hCAP-D3 may also be used as a biomarker to monitor the effectiveness of various therapeutic approaches. For example, hCAP-D3 has been shown to be downregulated in individuals with chronic pain, and may serve as a potential biomarker for assessing the effectiveness of various pain treatments.

Conclusion

hCAP-D3 is a promising natural product with a diverse chemical profile and potential as a drug target and biomarker. Its anti-inflammatory and analgesic effects suggest that it may have a wide range of therapeutic applications in various diseases. Further research is needed to fully understand the mechanisms by which hCAP-D3 interacts with the human body and to explore its potential as a drug target and biomarker.

Protein Name: Non-SMC Condensin II Complex Subunit D3

Functions: Regulatory subunit of the condensin-2 complex, a complex which establishes mitotic chromosome architecture and is involved in physical rigidity of the chromatid axis (PubMed:14532007). May promote the resolution of double-strand DNA catenanes (intertwines) between sister chromatids. Condensin-mediated compaction likely increases tension in catenated sister chromatids, providing directionality for type II topoisomerase-mediated strand exchanges toward chromatid decatenation. Specifically required for decatenation of centromeric ultrafine DNA bridges during anaphase. Early in neurogenesis, may play an essential role to ensure accurate mitotic chromosome condensation in neuron stem cells, ultimately affecting neuron pool and cortex size (PubMed:27737959)

The "NCAPD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCAPD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets